Koizumi et al. BMC Cancer 2010, 10:423 http://www.biomedcentral.com/1471-2407/10/423 bone metastasis from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 2005, 23:3314-3321. 13. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG: American society clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 2000, 18:1378-1391. 14. Koizumi M, Yoshimoto M, Kasumi F, Ogata E: Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003, 14:1234-1240. 15. Pedrazzini A, Gelber R, Isley M, Castiglione M, Goldhirsch A: First repeated bone scan in observation of patients with operable breast cancer. J Clin Oncol 1986, 4:389-394. 16. Sobin LH, Wittekind Ch, editors: UICC, TNM classification of malignant tumours. New York: Wiley-Liss, sixth 2002. 17. The Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer. Tokyo: Kimbara, 14 2000. 18. Sakamoto G: Infiltrating carcinoma: major histological types. Diagnostic histopathology of the breast New York: Churchill LivingstonePage DL, Anderson TJ 1987, 193-235. 19. Font D, Schneck SO, Frankel A, Robinson E: Bone metastases and bone pain in breast cancer. Are they closely associated? JAMA 1979, 242:1747-1748. 20. Koizumi M, Ogata E: Bone metabolic markers as gauges of metastasis to bone: a review. Ann Nucl Med 2002, 16:161-168. 21. Koizumi M, Takahashi S, Ogata E: Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 2003, 23:4095-4100. 22. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tankó LB: The relative utility of eight collagenous and non-collagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiology, Biomarkers & Prevention 2006, 15:32-38. 23. Cook GS, Houston S, Rubens R, Maisey MN, Fogelman I: Detection of bone metastases in breast cancer by 18FDG PET differing metabolic activity in osteoblastic and osteolytic lesion. J Clin Oncol 1998, 10:3357-3359. 24. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, Suzuki T, Nishimura T: Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005, 32:1253-1258. 25. Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, Neumaier B, Trager H, Nussle K, Reske SN: Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET. J Nucl Med 1999, 40:1623-1629. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/10/423/prepub doi:10.1186/1471-2407-10-423 Cite this article as: Koizumi et al.: Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain. BMC Cancer 2010 10:423. Page 9 of 9 Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit